15,646 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Natural Investments LLC

Natural Investments LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,646 shares of the company's stock, valued at approximately $1,345,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $42,000. Mesirow Financial Investment Management Inc. lifted its stake in Novo Nordisk A/S by 7.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 11,610 shares of the company's stock worth $1,382,000 after purchasing an additional 763 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in Novo Nordisk A/S by 31.3% during the third quarter. Crossmark Global Holdings Inc. now owns 52,596 shares of the company's stock valued at $6,263,000 after buying an additional 12,539 shares during the period. Ashton Thomas Securities LLC grew its stake in shares of Novo Nordisk A/S by 20.8% during the third quarter. Ashton Thomas Securities LLC now owns 11,024 shares of the company's stock valued at $1,313,000 after buying an additional 1,899 shares during the last quarter. Finally, Kennebec Savings Bank purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $106,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.0 %

NYSE:NVO traded down $0.82 during trading hours on Tuesday, hitting $78.14. The company had a trading volume of 7,426,424 shares, compared to its average volume of 5,357,347. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a 50-day moving average price of $84.61 and a 200 day moving average price of $104.04. The company has a market capitalization of $350.63 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $77.02 and a 52 week high of $148.15.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.